PROGENICS PHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | $4.3M | $3.2M | $11.7M | $69.4M | $8.7M | $44.4M |
| Operating income | −$18.2M | −$12.4M | −$58.4M | $13.1M | −$39.3M | $3.4M |
| Net income | −$68.6M | −$67.7M | −$51.0M | $10.8M | −$39.1M | $4.4M |
| Total assets | $119.5M | $169.5M | $146.0M | $199.0M | $131.3M | $161.0M |
| Total liabilities | $72.9M | $68.4M | $82.5M | $94.2M | $40.6M | $36.1M |
| Equity | $46.6M | $101.1M | $63.5M | $104.8M | $90.5M | $124.9M |
| EPS (diluted) | — | $-0.87 | $-0.73 | $0.15 | $-0.56 | $0.06 |
| Shares out. | 84.5M | 72.7M | 70.2M | 69.9M | 69.6M | 69.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- −426.0%
- Net margin
- −1601.3%
- Return on equity
- −147.3%
- Return on assets
- −57.4%
- Return on capital (ROCE)
- −18.7%
- Liabilities / assets
- 61.0%
- Debt / equity
- 1.57×
- Book value / share
- $0.55
- Revenue growth (YoY)
- 34.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- -16.56distress
- Accruals / assets
- 5.1%moderate
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventJun 22, 2020
- Shareholder voteJun 17, 2020
- Other material eventJun 16, 2020
- Director / officer changeJun 11, 2020
- Other material eventJun 8, 2020
- New financial obligationMay 28, 2020
- Regulation FD disclosureMay 18, 2020
- Results of operations · Regulation FD disclosureMay 7, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AAMENDMENT #3Feb 8, 2022
- SC 13G/AAMENDMENT NO. 2Feb 16, 2021
- 15-12GJul 2, 2020
- EFFECTJun 26, 2020
- 4FORM 4Jun 23, 2020
- 4FORM 4Jun 23, 2020
- 4FORM 4Jun 23, 2020
- 4FORM 4Jun 23, 2020
- 4FORM 4Jun 23, 2020
- 4FORM 4Jun 23, 2020
- 4FORM 4Jun 23, 2020
- 4FORM 4Jun 23, 2020
- 4FORM 4Jun 23, 2020
- 4FORM 4Jun 23, 2020
- 4FORM 4Jun 23, 2020
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.